Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Plug Power Inc (PLUG) vs BIO-TECHNE Corp (TECH) Price & Performance

Plug Power IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Plug Power Inc vs BIO-TECHNE Corp — how do they compare? Plug Power Inc trades at $1.69 (market cap $2.42B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 4.7× Plug Power Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 41 Days and BIO-TECHNE Corp for 64 Days on average.

PLUGTECH
Market Cap
$2.42B$11.36B
Volume
53,851,7025,390,331
Sector
IndustrialsHealth
52-Week High
$4.14$72.61
52-Week Low
$1.73$43.31
Typical Hold Time
41 Days64 Days
Enterprise Value
$3.29B$11.39B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Plug Power Inc

Plug Power (PLUG) trades at $1.715, down 3.65% on the day, reflecting ongoing operational challenges despite recent positive developments. The stock shows bearish technical signals with negative moving averages, though oscillators suggest potential oversold conditions. Fundamentally, the company continues to report significant losses with a net income margin of -220.59% and negative cash flow from operations of $535.84 million in 2025. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, providing some optimism for future growth in the green hydrogen sector.

The outlook remains challenging with persistent financial losses and high cash burn, though analyst consensus suggests potential upside with a $3.13 price target. Key risks include execution challenges in scaling hydrogen infrastructure, competitive pressures, and dependence on external financing. Investment opportunity exists for those betting on long-term hydrogen adoption, but requires high risk tolerance given current financial instability and market volatility.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.

The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PLUG
54% Buy46% Sell
Avg holding period · 41 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Plug Power Inc

Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.

Read more on PLUG →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →